Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00608023 · ClinicalTrials.gov registry record · Phase 3
TH9507 Extension Study in Patients With HIV-Associated Lipodystrophy
A Phase 3 study, sponsored by Theratechnologies.
- Completed
- Registry status
- Phase 3
- Development phase
- 263
- Enrollment target
NCT00608023 is a Phase 3 study that has completed, run by Theratechnologies. The registered enrollment target is 263 participants.
The verdict
NCT00608023, a Phase 3 study, has completed, sponsored by Theratechnologies.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 263 participants
- Enrollment target
Study Summary
Assessing the Efficacy and Long-Term Safety of a 2 mg dose of TH9507, a Growth Hormone-Releasing Factor Analog, in HIV Subjects with Excess Abdominal Fat Accumulation
Interventions
- DRUG Tesamorelin
- DRUG Placebo for Tesamorelin
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 263 participants |
| Start Date | 2007-08 |
| Est. Completion | 2008-10 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00608023
The ClinicalTrials.gov registry entry for NCT00608023 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 263 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Theratechnologies, which has 7 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Tesamorelin is the first listed.
NCT00608023 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00608023 about?
NCT00608023 is a clinical study titled "TH9507 Extension Study in Patients With HIV-Associated Lipodystrophy". Assessing the Efficacy and Long-Term Safety of a 2 mg dose of TH9507, a Growth Hormone-Releasing Factor Analog, in HIV Subjects with Excess Abdominal Fat Accumulation
What is the current status of trial NCT00608023?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 263 participants. The study started on 2007-08. Estimated completion is 2008-10.
What interventions are being tested in trial NCT00608023?
The interventions under investigation include: Tesamorelin (DRUG), Placebo for Tesamorelin (DRUG).
Who is sponsoring clinical trial NCT00608023?
This trial is sponsored by Theratechnologies, which has 7 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.